Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’

被引：0
|
作者：
Amir Ansaripour
Carin A. Uyl-de Groot
W. Ken Redekop
机构：
[1] Erasmus University Rotterdam,Institute for Medical Technology Assessment, Erasmus School of Health Policy and Management
来源：
PharmacoEconomics | 2018年 / 36卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：381 / 382
页数：1
相关论文
共 50 条
  • [1] Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"'
    Ansaripour, Amir
    Uyl-de Groot, Carin A.
    Redekop, W. Ken
    [J]. PHARMACOECONOMICS, 2018, 36 (03) : 381 - 382
  • [2] Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
    Amir Ansaripour
    Carin A. Uyl-de Groot
    W. Ken Redekop
    [J]. PharmacoEconomics, 2018, 36 : 91 - 103
  • [3] Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
    Ansaripour, Amir
    Uyl-de Groot, Carin A.
    Redekop, W. Ken
    [J]. PHARMACOECONOMICS, 2018, 36 (01) : 91 - 103
  • [4] Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
    Amir Ansaripour
    Carin A. Uyl-de Groot
    W. Ken Redekop
    [J]. PharmacoEconomics, 2018, 36 : 505 - 505
  • [5] Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy (vol 36, pg 91, 2018)
    Ansaripour, Amir
    Uyl-de Groot, Carin A.
    Redekop, W. Ken
    [J]. PHARMACOECONOMICS, 2018, 36 (04) : 505 - 505
  • [6] Cost-effectiveness analysis of adjuvant therapy with trastuzumab for HER2-positive early breast cancer in polish setting
    Orlewska, E.
    Pienkowski, T.
    Drosik, K.
    Gyldmark, M.
    Aultman, R.
    Szkultecka-Debek, M.
    [J]. VALUE IN HEALTH, 2007, 10 (03) : A125 - A125
  • [7] Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
    Garrison, Louis R., Jr.
    Lubeck, Deborah
    Lalla, Deepa
    Paton, Virginia
    Dueck, Amylou
    Perez, Edith A.
    [J]. CANCER, 2007, 110 (03) : 489 - 498
  • [8] COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE SAUDI ARABIAN SETTING
    AlOmar, H.
    Zazaa, A. S.
    AlFayyadh, M.
    Ray, J. A.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A465 - A466
  • [9] COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER
    Nguyen, T. T. T.
    Yagudina, R.
    Kulikov, A. U.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A165 - A165
  • [10] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Schwartz, Naomi R. M.
    Flanagan, Meghan R.
    Babigumira, Joseph B.
    Steuten, Lotte M.
    Roth, Joshua A.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (10): : 1133 - 1139
12345